0000000000454996

AUTHOR

Carmen Martín Calvo

showing 3 related works from this author

Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell…

2021

The potential role of active CMV infection in promoting acute Graft-versus-Host Disease (aGvHD) in allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a matter of debate. We further addressed this issue conducting a retrospective, observational, multicenter study of 632 patients subjected to allogeneic peripheral blood HSCT at 20 Spanish centers. Monitoring of CMV DNA load in plasma or whole blood was performed by real-time PCR assays. Cumulative incidence of CMV DNAemia was 48.9% (95% CI, 45%-52.9%), of any grade aGvHD, 45.6; 95% (CI, 41.3%-50.1%), and of grade II-IV aGvHD, 30.7 (95% CI, 24.9%-36.4%). Overall, development of CMV DNAemia at any level resulted in an increa…

medicine.medical_specialtyversus&#8208medicine.medical_treatmentCongenital cytomegalovirus infectionCytomegalovirusGraft vs Host DiseaseDiseaseHematopoietic stem cell transplantationCMV DNAemia030230 surgeryGastroenterologyCMV DNAemia acute graft-versus-host disease allogeneic hematopoietic stem cell transplantation cytomegalovirus (CMV)Cell therapy03 medical and health sciences0302 clinical medicineInternal medicinehemic and lymphatic diseasesMedicineHumansCumulative incidenceallogeneic hematopoietic stem cell transplantationWhole bloodRetrospective StudiesTransplantationhost diseasePeripheral Blood Stem Cell Transplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesmedicine.diseaseacute graft&#8208TransplantationHaematopoiesisInfectious Diseasessurgical procedures operativecytomegalovirus (CMV)030211 gastroenterology & hepatologybusinessTransplant infectious disease : an official journal of the Transplantation SocietyREFERENCES
researchProduct

Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transpla…

2020

The net impact of cytomegalovirus (CMV) DNAemia on overall mortality (OM) and nonrelapse mortality (NRM) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a matter of debate. This was a retrospective, multicenter, noninterventional study finally including 749 patients. CMV DNA monitoring was conducted by real-time polymerase chain reaction (PCR) assays. Clinical outcomes of interest were OM and NRM through day 365 after allo-HSCT. The cumulative incidence of CMV DNAemia in this cohort was 52.6%. A total of 306 out of 382 patients with CMV DNAemia received preemptive antiviral therapy (PET). PET use for CMV DNAemia, but not the occurrence of CMV DNAemia, taken …

Oncologymedicine.medical_specialtybone marrowinfection and infectious agents - viralmedicine.medical_treatmentCongenital cytomegalovirus infectionCytomegaloviruscomplicationHematopoietic stem cell transplantation030230 surgerylaw.inventionCell therapy03 medical and health sciences0302 clinical medicinelawInternal medicinehemic and lymphatic diseasesRisk of mortalityImmunology and AllergyMedicineHumansTransplantation HomologousPharmacology (medical)Cumulative incidencePolymerase chain reactionRetrospective StudiesTransplantationbusiness.industryHematopoietic Stem Cell Transplantationvirus diseasesmedicine.diseasepracticeTransplantationinfectious infection and infectious agents - viral: Cytomegalovirus (CMV) [bone marrow/hematopoietic stem cell transplantation clinical research/practice complication]infectiousclinical researchCohortCytomegalovirus InfectionsDNA Viralhematopoietic stem cell transplantationCytomegalovirus (CMV)business
researchProduct

Allogeneic Hematopoietic Stem Cell Transplantation for T Cell Lymphomas: Improved Results Overtime

2019

INTRODUCTION: Allogeneic hematopoietic stem cell transplantation (alloSCT) is the only curative strategy for relapsed/refractory T cell lymphoma (T-NHL). In the past ten years, there have been several improvements in conditioning regimens and graft versus host disease prophylaxis (GVHD), which have contributed to lower transplant-related mortality (TRM). Also, selective and low toxicity therapies, might improve response quality in some T-NHL Recently, haploidentical stem cell transplantation (Haplo) with post-transplant cyclophosphamide is a new option for those patients who do not have an HLA-identical sibling or a suitable unrelated donor, but also it has shortened the time for urgent cas…

medicine.medical_specialtyeducation.field_of_studybusiness.industrymedicine.medical_treatmentImmunologyPopulationCell BiologyHematologyHematopoietic stem cell transplantationmedicine.diseaseBiochemistryTransplantationGraft-versus-host diseaseAutologous stem-cell transplantationMedian follow-upInternal medicinemedicineCumulative incidenceeducationbusinessProgressive disease
researchProduct